Stockreport

Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF drug, Anktiva, beyond its initial approval in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). While the current label establishes a commercial foothold, the [Read more]